Navigational, measuring, medical and control instruments manufacturing

Canada has 640 establishments in this code and it is not one market: it runs from navigation and guidance electronics through laboratory and industrial process instruments to the medical devices Statistics Canada files alongside them. What they share is the reason a better sensor is not a business. Nothing here is bought on the instrument alone. A device used to buy or sell anything by measure in Canada cannot be sold into trade until its design is approved — Measurement Canada’s own wording is that "You must obtain a type approval to confirm that a particular measuring device complies with all applicable legal requirements and can be marked for use in trade" [A] — and the medical instruments in this group face the same pattern under Health Canada. Approval attaches to the design, so each variant re-enters the queue, and the cost is sunk before a unit ships. Above that sits the engineering. Teledyne Technologies spent US$317.3M on research and development in 2025 on US$6,115.4M of sales [A], and its Instrumentation segment earned US$400.4M on US$1,457.1M — a 27.5% operating margin [A]. That margin is the point rather than a complaint about it: incumbents here are well paid, and what they are paid for is a qualification an entrant has to buy twice — once from the regulator, and again from a customer who will not put an unproven instrument into a process or a patient it cannot stop. 408 of the 640 Canadian establishments have fewer than twenty employees, so small firms plainly survive; each lives on one or two approved product lines sold to customers it already knows. Entering means funding a line all the way to approval with nothing coming in, and then doing it again for the next variant. Which niche inside the group is most reachable — process instruments, marine, or a medical device — was not tested here and is where a study would start.

The demand is real and growing fast. Axon's Platform Solutions line, which holds its drones, counter-drone kit and fixed cameras, rose 122.6% to $149.8M in Q2 2026 [A]. Flock Safety reported more than $300M of annual recurring revenue, up 70%, when it raised $275M at a $7.5B valuation [A, company release]. From 22 December 2025 the FCC also put new foreign-made drone models on its Covered List [A]. The cut is that police buy a network, not a device. A drone or a plate camera earns its keep only when it plugs into the dispatch, evidence and real-time crime-centre software the agency already runs, and the three firms that own that software have already picked their drone makers. Flock bought Aerodome in October 2024. Axon owns Dedrone and integrates Skydio. Motorola has invested in Brinc twice, the second time with $100M on 1 July 2026 [A]. Contracts run for years: Axon carries $9.8B of remaining performance obligations [A]. The listed specialists outside those platforms show where an independent ends up. ShotSpotter-maker SoundThinking grew 2% to $104.1M and lost $9.4M in 2025 after Chicago ended its contract [A]. Rekor's own Q2 2026 10-Q raises substantial doubt about its ability to continue as a going concern [A]. Politics adds churn without opening a door: Austin halted Flock in June 2025 and Pflugerville ended its contract in August 2026 over outside-agency data access [B], while Connecticut now caps plate data at 21 days and New Mexico bars sharing it for immigration enforcement [B]. A city that cancels Flock usually moves to another incumbent. In Canada the opening is narrower still: the new lower-risk BVLOS category keeps drones 1 km from populated areas [A], so urban DFR still runs on special approval. Distribution decides it.

The category grows, and the margins are attractive once a company is big. Garmin's Fitness segment sold $2,357M in 2025, up 33%, at a 31% operating margin [A], and it kept growing in 2026: $757M in the second quarter, up 25%, with a 37% segment operating margin [A]. Oura's revenue went from $406.8M (fiscal 2024) to $907.9M (fiscal 2025), and $1,214.5M in the nine months to June 2026, up 74% [A]. The subscription layer looks best of all: Oura charges $5.99 a month or $69.99 a year on top of a $349–$499 ring, and its membership revenue ran at an 89% gross margin [A]. But each of those numbers was bought with hardware capital. Oura raised about $1.5B in preferred stock over twelve years before filing to list, $908M of it in September 2025 [A]; Whoop raised a $575M Series G at a $10.1B valuation in March 2026 [B]; Zepp Health, which sells Amazfit watches at $258.9M of revenue, still lost $40.1M in 2025 on a 38% gross margin [A]. An entrant must fund sensors, validation studies, tooling, inventory and a phone app before the first sale, and then defend it in court: Samsung filed an ITC complaint against Oura in December 2025 seeking import restrictions [A], and Ultrahuman was out of the US market under an ITC import ban until it settled with Oura [B]. Above the hardware sit the phone platforms — Apple held 18–21% of global wearable units in each quarter of 2025 [B], and Apple, Samsung, Google (Fitbit, bought for $2.1B in 2021 [A]), Huawei and Xiaomi bundle their health features into their phones' ecosystems. Medical claims add a regulatory step: ECG apps from Apple, Samsung, Fitbit, Garmin, Withings and Whoop all went through FDA De Novo or 510(k) [A], and in Canada software that only encourages a healthy lifestyle is not a medical device, but software that analyses physiological signals generally is (Class II) [A]. Capital intensity decides it: the open lanes are app-only (Strava, Runna, TrainingPeaks) or narrow sensors (Hexoskin shirts, Muse EEG headbands), and even Strava's app layer needed a $2.2B-valuation round in 2025 [B]. This record covers consumer devices and their membership apps; gym and studio management software is 713940, and EGYM's software is researched separately.